Site search
2831 results for '' found
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
/
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
/
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmon
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmon
/
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
/
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
/
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyp
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyp
/
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
/
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
/
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of
/
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibi
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibi
/